16-Week Data From SALWEEN Fill the Gap for Patients With PCV - Takeaways - MDSpire

16-Week Data From SALWEEN Fill the Gap for Patients With PCV

Discover insights from Professor Gemmy Cheung as she discusses the promising first-time data from the SALWEEN study on the use of faricimab in patients with polypoidal choroidal vasculopathy (PCV).

  • By

  • Gemmy Cheung, MBBS, FRCOphth, FAMS, MCI

  • Michael A. Singer, MD

  • March 1, 2025

  • 9 min

Share

  • 1

    The SALWEEN study investigates the efficacy and safety of faricimab in patients with polypoidal choroidal vasculopathy (PCV).

  • 2

    By week 16, patients in the SALWEEN study experienced an average BCVA gain of over seven letters and a reduction in CST to just over 400 μm.

  • 3

    The polyp closure rate at week 16 was 51%, indicating a robust response to treatment compared to previous monotherapy studies.

  • 4

    More than 80% of eyes showed no active polyps, suggesting effective disease control in the SALWEEN trial.

  • 5

    The study's ongoing design allows for flexible retreatment intervals based on disease activity, aiming to optimize patient outcomes.

Original Source(s)

16-Week Data From SALWEEN Fill the Gap for Patients With PCV

  • by Gemmy Cheung, MBBS, FRCOphth, FAMS, MCI, Michael A. Singer, MD

  • March 1, 2025

Related Content

Osteoporosis Linked to Increased Dry AMD Risk

Genetic and pooled observational data suggest a unidirectional association, with elevated odds of dry age-related macular degeneration and a stronger signal in women.

Suspected Ocular Toxoplasmosis in Patients with ABCA4-Related Maculopathy

Diagnosing and Managing Polypoidal Choroidal Vasculopathy

Polypoidal choroidal vasculopathy (PCV) is a distinct choroidal vascular disorder often considered a variant of age-related macular degeneration (AMD), although features such as drusen, pigmentary changes, and geographic atrophy are uncommon.